Targeting inflammation: the emerging role of JAK inhibitors in dermatologic and rheumatologic pharmacotherapy

Background Janus kinase (JAK) inhibitors have changed the treatment of immune-mediated dermatologic and rheumatologic disease by targeting intracellular cytokine signaling. The ORAL Surveillance trial and the regulatory actions that followed made safety a primary determinant of clinical positioning. Interpretation depends on separating what has been shown for a given molecule in a given population from what has been extrapolated across a heterogeneous class. Methods We performed a narrative review of PubMed and MEDLINE through 31 July 2026, supplemented by reference lists and by United States Food and Drug Administration (FDA) and European Medicines Agency (EMA) documents. Available studies were eligible if they informed the pharmacology, efficacy, safety, or regulatory status of JAK-pathway inhibitors. Evidentiary weight was assigned hierarchically by study design. Results Efficacy is established in rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, juvenile idiopathic arthritis, giant cell arteritis, atopic dermatitis, alopecia areata, plaque psoriasis, vitiligo, and chronic hand eczema. Filgotinib, a JAK1-preferential inhibitor authorized in Europe and Japan but not the United States, is reviewed alongside FDA-approved agents. ORAL Surveillance found higher rates of major adverse cardiovascular events (3.4% versus 2.5%) and malignancy (4.2% versus 2.9%) with tofacitinib than with tumor necrosis factor inhibitors among patients with rheumatoid arthritis aged 50 years or older with at least one cardiovascular risk factor. Regulators then extended warnings across systemic agents, whereas direct evidence for other molecules, routes, and indications remains uneven. Selectivity has not been shown to confer safety superiority. Conclusion These agents are pharmacologically diverse rather than uniform. Selection should follow indication, treatment history, route, and baseline cardiovascular, malignancy, thromboembolic, infectious, and reproductive risk, with structured screening and monitoring. Long-term comparative safety data remain incomplete.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2026-11-12
DOI
https://doi.org/10.3389/fphar.2026.1955209
Primary Topic
Rheumatoid Arthritis Research and Therapies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Targeting inflammation: the emerging role of JAK inhibitors in dermatologic and rheumatologic pharmacotherapy

Yash C. Jani, Karan Rajalingam, Karthik Krishnamurthy, Anthony Thompson et al.
Frontiers in Pharmacology
Rheumatoid Arthritis Research and Therapies
article

Targeting inflammation: the emerging role of JAK inhibitors in dermatologic and rheumatologic pharmacotherapy

Yash C. Jani, Karan Rajalingam, Karthik Krishnamurthy, Anthony Thompson, Brett R Shaffer, Milaan Shah, Preet C. Jani, David Cohen
article en

Abstract

Background Janus kinase (JAK) inhibitors have changed the treatment of immune-mediated dermatologic and rheumatologic disease by targeting intracellular cytokine signaling. The ORAL Surveillance trial and the regulatory actions that followed made safety a primary determinant of clinical positioning. Interpretation depends on separating what has been shown for a given molecule in a given population from what has been extrapolated across a heterogeneous class. Methods We performed a narrative review of PubMed and MEDLINE through 31 July 2026, supplemented by reference lists and by United States Food and Drug Administration (FDA) and European Medicines Agency (EMA) documents. Available studies were eligible if they informed the pharmacology, efficacy, safety, or regulatory status of JAK-pathway inhibitors. Evidentiary weight was assigned hierarchically by study design. Results Efficacy is established in rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, juvenile idiopathic arthritis, giant cell arteritis, atopic dermatitis, alopecia areata, plaque psoriasis, vitiligo, and chronic hand eczema. Filgotinib, a JAK1-preferential inhibitor authorized in Europe and Japan but not the United States, is reviewed alongside FDA-approved agents. ORAL Surveillance found higher rates of major adverse cardiovascular events (3.4% versus 2.5%) and malignancy (4.2% versus 2.9%) with tofacitinib than with tumor necrosis factor inhibitors among patients with rheumatoid arthritis aged 50 years or older with at least one cardiovascular risk factor. Regulators then extended warnings across systemic agents, whereas direct evidence for other molecules, routes, and indications remains uneven. Selectivity has not been shown to confer safety superiority. Conclusion These agents are pharmacologically diverse rather than uniform. Selection should follow indication, treatment history, route, and baseline cardiovascular, malignancy, thromboembolic, infectious, and reproductive risk, with structured screening and monitoring. Long-term comparative safety data remain incomplete.

Frontiers in PharmacologyVol. 17
University of Central Florida (US), Mercer University (US), Medical University of South Carolina (US), Mercer University Health Sciences Center (US), HCA Florida Orange Park Hospital (US), Wake Forest University (US)
Good health and well-being
Rheumatoid Arthritis Research and Therapies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon